Join
Live feed
·
PRReleasevia Quantisnow
Palvella Therapeutics Inc. logo

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

ByQuantisnow·Wall Street's wire, on your screen.
PVLA· Palvella Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PVLA (Palvella Therapeutics Inc.) and more on Quantisnow.